Micardis Plus

Per 40/12.5 mg tab Telmisartan 40 mg, hydrochlorothiazide 12.5 mg. Per 80/12.5 mg tab Telmisartan 80 mg, hydrochlorothiazide 12.5 mg

Essential HTN when BP is inadequately controlled by telmisartan or hydrochlorothiazide alone.

Adult 1 tab once daily. Mild to moderate hepatic impairment Not >40/12.5 mg once daily.

May be taken with or without food.

Hypersensitivity to telmisartan, hydrochlorothiazide or to other sulphonamide-derived substances. Cholestasis, biliary obstructive disorders, severe hepatic & renal impairment (CrCl <30 mL/min), refractory hypokalaemia, hypercalcaemia. Therapy-refractory hyponatraemia, hypovolaemia, symptomatic hyperuricaemia/gout. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Pregnancy (2nd & 3rd trimesters) & lactation.

Renovascular HTN, hepatic & renal impairment & kidney transplant, intravascular vol depletion, CHF, renal artery stenosis, primary aldosteronism, aortic & mitral valve stenosis, obstructive hypertrophic cardiomyopathy, DM, electrolyte imbalance. Ischaemic cardiopathy or ischaemic CV disease. Dual blockade of the renin-angiotensin-aldosterone system. Acute myopia & secondary angle-closure glaucoma. Patients w/ rare hereditary conditions of galactose intolerance eg, galactosaemia. Patient w/ hereditary fructose intolerance, Na, choroidal effusion, non-melanoma skin cancer. May impair ability to drive or operate machinery. Childn & adolescents ≤18 yr.

Bronchitis, pharyngitis, sinusitis; URTI, UTI, cystitis, sepsis (including fatal outcome); basal cell carcinoma, skin, lip squamous cell carcinoma; anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, aplastic anaemia, haemolytic anaemia, bone marrow failure, leukopenia, agranulocytosis; lupus erythematosus, vasculitis necrotising, anaphylactic reaction, hypersensitivity, DM inadequare control; hypokalaemia, hyponatraemia, hyperuricaemia, hyperkalaemia, hypoglycaemia (in diabetic patients), hypovolaemia, electrolyte imbalance; decreased appetite, hyperglycaemia, hyperlipidemia; hypomagnesaemia, hypercalcaemia, hypochloraemic alkalosis, glycosuria; anxiety, depression, restlessness; dizziness, syncope (faint), paraesthesia, sleep disorder, insomnia, headache; visual impairment, blurred vision, angle-closure glaucoma, choroidal effusion; vertigo; arrhythmia, tachycardia, bradycardia; hypotension, orthostatic hypotension; dyspnoea, resp distress, pneumonitis, pulmonary oedema; diarrhoea, dry mouth, flatulence, abdominal pain, constipation, dyspepsia, vomiting, gastritis; abdominal discomfort, pancreatitis, nausea, abnormal hepatic function/liver disorder, jaundice (cholestasis intrahepatic); angioedema (w/ fatal outcome), erythema, pruritus, rash, hyperhidrosis, urticaria, eczema, drug eruption, toxic skin eruption, TEN, lupus like syndrome (drug-induced cutaneous lupus erythematosus), photosensitivity reaction, erythema multiforme; back pain, muscle spasm (cramps in leg), myalgia, arthralgia, pain in extremity (leg pain), tendon pain (tendonitis like symptoms); renal impairment (including acute renal injury); erectile dysfunction; chest pain, influenza-like illness, pain, asthenia (weakness), pyrexia; blood uric acid increased, blood creatinine increased, hepatic enzyme increased, hepatic enzyme increased, blood creatinine phosphokinase increased, haemoglobin decreased.

K-sparing diuretics, K supplements, salt substitutes containing K or other drugs that may increase serum K levels (especially heparin, digoxin, lithium). May increase hypotensive effect of other antihypertensives. Alcohol, barbiturates, narcotics, antidiabetics, cholestyramine & colestipol resins, digitalis glycosides, pressor amines, nondepolarising skeletal muscle relaxant, uricosuric agents, Ca salts. β-blockers, diazoxide, anticholinergic agents, amantadine, cytotoxic drugs.

Angiotensin II Antagonists

C09DA07 - telmisartan and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.

G